BMY
Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and nutritional products. The company operates in two segments namely Pharmaceuticals and Nutritionals.
Bristol-Myers Squibb Company (BMY) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (A-); its weakest is Revisions (D-). The rating has held at C+ for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-16 | B (3.2) | C- (1.9) | A- (3.9) | B (3.2) | D- (0.8) | C+ (2.6) |
| 2026-11-09 | B (3.2) | C- (1.9) | A- (3.9) | B (3.2) | D- (0.8) | C+ (2.6) |
| 2026-11-06 | B (3.2) | C- (1.9) | A- (3.9) | B- (3.1) | C- (2.1) | C+ (2.8) |
| 2026-11-05 | B (3.2) | C- (1.9) | A- (3.9) | B- (3.0) | C- (2.1) | C+ (2.8) |
| 2026-11-04 | B (3.2) | C- (1.9) | A- (3.9) | B- (3.0) | C (2.2) | C+ (2.8) |